IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.046 |
52 Week High | AU$0.21 |
52 Week Low | AU$0.046 |
Beta | 2.41 |
1 Month Change | -30.30% |
3 Month Change | -49.45% |
1 Year Change | -74.44% |
3 Year Change | -9.80% |
5 Year Change | 109.09% |
Change since IPO | -52.82% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sep 19We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
May 30Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Jan 30Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More
Nov 11Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Aug 22Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Feb 28A Look At Imugene's (ASX:IMU) CEO Remuneration
Feb 17Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
Dec 24Shareholder Returns
IMU | AU Biotechs | AU Market | |
---|---|---|---|
7D | -8.0% | -0.5% | -0.3% |
1Y | -74.4% | -11.3% | 7.5% |
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -11.4% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned 5.9% over the past year.
Price Volatility
IMU volatility | |
---|---|
IMU Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 10.9% |
Market Average Movement | 8.4% |
10% most volatile stocks in AU Market | 15.8% |
10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: IMU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IMU's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | n/a | Leslie Chong | https://www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.
Imugene Limited Fundamentals Summary
IMU fundamental statistics | |
---|---|
Market Cap | AU$329.34m |
Earnings (TTM) | -AU$39.17m |
Revenue (TTM) | AU$10.52m |
31.3x
P/S Ratio-8.4x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMU income statement (TTM) | |
---|---|
Revenue | AU$10.52m |
Cost of Revenue | AU$0 |
Gross Profit | AU$10.52m |
Other Expenses | AU$49.69m |
Earnings | -AU$39.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0055 |
Gross Margin | 100.00% |
Net Profit Margin | -372.30% |
Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparison